文献速递慢阻肺哮喘呼吸道感染

澳大利亚夏季降阶维持性大环内酯类治疗对阻塞性气道疾病急性加重的影响:随机双盲安慰剂对照试验

Effect of maintenance macrolide de-escalation during the Australian summer on exacerbations of obstructive airway diseases: a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Thorax · 2026-07-28

该双盲、安慰剂对照、非劣效性试验纳入82例接受维持性大环内酯类治疗的阻塞性气道疾病患者,在夏季开始时随机继续或降阶大环内酯治疗。夏季急性加重率继续组33.3%(14/42)、降阶组50%(19/38),风险差16.2%(95%CI -4.9%至37.2%),未证明非劣效;继续组首次加重时间更长(中位206 vs 90天;HR 1.98,95%CI 1.15-3.42;p=0.012)。

要点

  • 夏季降阶维持性大环内酯未达非劣效,急性加重风险差16.2%(95%CI -4.9%至37.2%)
  • 继续组首次加重时间中位206天,降阶组90天(HR 1.98,95%CI 1.15-3.42;p=0.012)
  • 症状控制两组维持且无差异,但降阶仍存加重复发风险

核心结论

  • 在阻塞性气道疾病患者中,夏季降阶维持性大环内酯治疗未证明非劣效于继续治疗。
  • 部分患者或可在夏季停用长期大环内酯,但仍存在急性加重复发风险。

研究设计与样本

  • 双盲、安慰剂对照、非劣效性随机试验,招募82例接受维持性大环内酯治疗的哮喘、慢阻肺或支气管扩张患者。
  • 参与者平均年龄67.33±13.13岁,55%为女性,在夏季(12月至2月)开始时随机分为继续组或降阶组。
  • 在第3、6、9个月进行随访访谈,主要结局为夏季急性加重,非劣效性界值为20%。

主要发现

  • 夏季急性加重率继续组为33.3%(14/42),降阶组为50%(19/38)。
  • 主要分析未证明非劣效性:风险差16.2%(95%CI -4.9%至37.2%),上限超过20%非劣效界值。
  • 症状控制评分两组维持且无差异。
  • 首次加重时间继续组中位206天,降阶组90天(HR 1.98,95%CI 1.15至3.42;p=0.012)。

关键数值与推荐

  • 非劣效性界值为20%。
  • 主要分析风险差16.2%(95%CI -4.9%至37.2%),未达非劣效。
  • 首次加重时间HR 1.98(95%CI 1.15至3.42;p=0.012)。

临床怎么用

  • 对接受维持性大环内酯治疗的阻塞性气道疾病患者,夏季降阶需权衡急性加重复发风险。
  • 部分患者或可考虑夏季停用,但应密切监测加重迹象。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal duration of maintenance macrolide antibiotic therapy in obstructive airway disease (OAD) remains unclear. This study evaluated the impact of de-escalating maintenance macrolide therapy during the Australian summer on OAD exacerbations. METHODS: This double-blind, placebo-controlled, non-inferiority trial recruited 82 participants (mean age: 67.33±13.13; 55% female) undergoing maintenance macrolide therapy for the management of asthma, chronic obstructive pulmonary disease or bronchiectasis. They were randomised to continue (continuation arm) or de-escalate macrolide therapy (de-escalation arm) at the start of the summer (December-February). Follow-up interviews were conducted at 3, 6 and 9 months. The primary outcome was acute exacerbations during the summer. Secondary outcomes included symptom control scores and time to first exacerbation. The non-inferiority margin was 20%. RESULTS: The acute exacerbation rates were 33.3% (14/42) for the continuation arm and 50% (19/38) for the de-escalation arm during the summer season. The primary analysis did not demonstrate non-inferiority (risk difference 16.2%; 95% CI -4.9% to 37.2%, with the upper bound exceeding the 20% non-inferiority margin). Symptom control was maintained and did not differ between arms. The time to first exacerbation was longer in the continuation arm (median 206 vs 90 days; HR 1.98, 95% CI 1.15 to 3.42; p=0.012). CONCLUSION: Macrolide de-escalation was not found to be non-inferior to continued treatment in individuals with OAD. While some patients may be able to discontinue long-term macrolide therapy during the summer, there remains a risk of exacerbation recurrence. TRIAL REGISTRATION NUMBER: ACTRN12620001263987.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Thomas D, McDonald V, Wark PA, et al. Effect of maintenance macrolide de-escalation during the Australian summer on exacerbations of obstructive airway diseases: a randomised, double-blind, placebo-controlled trial. Thorax. 2026. PMID: 42521618. doi:10.1136/thorax-2025-224164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。